1. Roelof W. F. van Leeuwen et al. Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options, Clinical Pharmacokinetics. 2017.7, Vol. 56, Issue 7, pp 683–688.
2. van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315–26.
3. European Medicines Agency. Europian Public Assessment Reports Assessment History and Product information.
http://www.ema./ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124. Accessed 19 Sep 2016.
4. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm. 2007;64(9 Suppl 5):S4–7.
5. Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412–22.
6. Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol. 2002;58(7):453–8.
7. Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2012;35(7):810–8.
8. Hunfeld NG, Touw DJ, Mathot RA, Mulder PG, Van Schaik RH, Kuipers EJ, et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2010;31(1):150
9. Ter Heine R, Fanggiday JC, Lankheet NA, Beijnen JH, Van Der Westerlaken MM, Staaks GH, et al. Erlotinib and pantoprazole: a relevant interaction or not? Br J Clin Pharmacol. 2010;70(6):908–11.
10. Barlow AP, Hinder RA, DeMeester TR, Fuchs K. Twenty-four-hour gastric luminal pH in normal subjects: influence of probe position, food, posture, and duodenogastric reflux. Am J Gastroenterol. 1994;89(11):2006–10.
11. van Leeuwen RW, Peric R, Hussaarts KG, Kienhuis E, IJzerman NS, de Bruijn P, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34(12):1309–14.